May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab (Avastin) Treatment of Choroidal Neovascularization Secondary to the Ocular Histoplasmosis Syndrome
Author Affiliations & Notes
  • D. G. Dodwell
    Ophthalmology, Springfield Clinic, Springfield, Illinois
  • O. Mansuri
    Southern Illinois University School of Medicine, Springfield, Illinois
  • Footnotes
    Commercial Relationships D.G. Dodwell, None; O. Mansuri, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 3391. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. G. Dodwell, O. Mansuri; Intravitreal Bevacizumab (Avastin) Treatment of Choroidal Neovascularization Secondary to the Ocular Histoplasmosis Syndrome. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3391.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: To evaluate the treatment of choroidal neovascularization (CNV) secondary to the ocular histoplasmosis syndrome (OHS) with intravitreal bevacizumab.

Methods:: Retrospective review of 10 eyes of ten consecutive patients, with 6 month follow-up, who received one or more intravitreal bevacizumab injections for either subfoveal or juxtafoveal CNV secondary to OHS. Outcome measures included visual acuity and optical coherence tomography (OCT).

Results:: Patients were observed for a median length of follow-up of 34 weeks (range, 23-44 weeks). Four eyes had prior treatment with photodynamic therapy or focal laser. Six eyes were treatment-naive. Pretreatment visual acuity ranged from 20/30 to 20/400 (mean, 20/80). Final visual acuity ranged from 20/25 to 20/100 (mean, 20/40). Mean logMar visual acuity increased from a pretreatment level of 0.58(20/80) to 0.46(20/63) at 4 weeks, 0.45(20/50) at 12 weeks and 0.42(20/50) at 26 weeks. Mean OCT thickness decreased from 310 microns pretreatment to 260 microns at 4 weeks, 230 microns at 12 weeks and 243 microns at 26 weeks. Five of ten eyes showed improvement in visual acuity by 3 or more lines at week 12 and week 26. Eight of ten patients maintained or improved visual acuity at week 12 and week 26. Two of 10 patients lost one line of visual acuity at week 26.

Conclusions:: Intravitreal bevacizumab may improve and/or maintain vision in both naïve and previously treated eyes for up to 6 months.

Keywords: choroid: neovascularization • fungal disease • growth factors/growth factor receptors 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.